Search results
Results from the WOW.Com Content Network
Pathophysiology of factor V Leiden gene mutation. Factor V Leiden is an autosomal dominant genetic condition that exhibits incomplete penetrance, i.e. not every person who has the mutation develops the disease. The condition results in a factor V variant that cannot be as easily degraded by activated protein C.
APC resistance is the inability of protein C to cleave Factor Va and/or Factor VIIIa, which allows for longer duration of thrombin generation and may lead to a hypercoagulable state. This may be hereditary or acquired. [4] The best known and most common hereditary form is Factor V Leiden, which is responsible for more than 95% of cases. [5]
Factor V is produced by megakaryocytes, which produce platelets and platelet-derived factor V, and hepatocytes, which produce plasma-derived factor V. [9] The molecule circulates in plasma as a single-chain molecule with a plasma half-life of 12–36 hours. [10] Factor V is able to bind to activated platelets and is activated by thrombin.
Heterozygous protein C deficiency occurs in 0.14–0.50% of the general population. [13] [14] Based on an estimated carrier rate of 0.2%, a homozygous or compound heterozygous protein C deficiency incidence of 1 per 4 million births could be predicted, although far fewer living patients have been identified. [6]
In medical genetics, compound heterozygosity is the condition of having two or more heterogeneous recessive alleles at a particular locus that can cause genetic disease in a heterozygous state; that is, an organism is a compound heterozygote when it has two recessive alleles for the same gene, but with those two alleles being different from each other (for example, both alleles might be ...
In fact, Factor V Leiden is the most common cause of inherited thrombosis. [26] Heterozygous factor V Leiden is present in approximately 5% of the white population in the United States and homozygous factor V Leiden is found less than 1% of this population. [27]
A new study is illuminating how “forever chemicals” can alter our brain cells by impairing the genes that maintain healthy neurons, the cells of our nervous system. Scientists are only ...
The minor ("type 2") thrombophilias are much more common. Factor V Leiden is present in 5% of the population of Northern European descent, but much rarer in those of Asian or African extraction. In people with thrombosis, 10% have factor V Leiden. In those who are referred for thrombophilia testing, 30–50% have the defect.